205 related articles for article (PubMed ID: 25352062)
41. Vincristine and bortezomib use distinct upstream mechanisms to activate a common SARM1-dependent axon degeneration program.
Geisler S; Doan RA; Cheng GC; Cetinkaya-Fisgin A; Huang SX; Höke A; Milbrandt J; DiAntonio A
JCI Insight; 2019 Sep; 4(17):. PubMed ID: 31484833
[TBL] [Abstract][Full Text] [Related]
42. The neuroprotective factor Wld(s) fails to mitigate distal axonal and neuromuscular junction (NMJ) defects in mouse models of spinal muscular atrophy.
Kariya S; Mauricio R; Dai Y; Monani UR
Neurosci Lett; 2009 Jan; 449(3):246-51. PubMed ID: 19010394
[TBL] [Abstract][Full Text] [Related]
43. WldS enhances insulin transcription and secretion via a SIRT1-dependent pathway and improves glucose homeostasis.
Wu J; Zhang F; Yan M; Wu D; Yu Q; Zhang Y; Zhou B; McBurney MW; Zhai Q
Diabetes; 2011 Dec; 60(12):3197-207. PubMed ID: 21998399
[TBL] [Abstract][Full Text] [Related]
44. Axonal Degeneration in Retinal Ganglion Cells Is Associated with a Membrane Polarity-Sensitive Redox Process.
Almasieh M; Catrinescu MM; Binan L; Costantino S; Levin LA
J Neurosci; 2017 Apr; 37(14):3824-3839. PubMed ID: 28275163
[TBL] [Abstract][Full Text] [Related]
45. dSarm/Sarm1 is required for activation of an injury-induced axon death pathway.
Osterloh JM; Yang J; Rooney TM; Fox AN; Adalbert R; Powell EH; Sheehan AE; Avery MA; Hackett R; Logan MA; MacDonald JM; Ziegenfuss JS; Milde S; Hou YJ; Nathan C; Ding A; Brown RH; Conforti L; Coleman M; Tessier-Lavigne M; Züchner S; Freeman MR
Science; 2012 Jul; 337(6093):481-4. PubMed ID: 22678360
[TBL] [Abstract][Full Text] [Related]
46. Role of SARM1 and DR6 in retinal ganglion cell axonal and somal degeneration following axonal injury.
Fernandes KA; Mitchell KL; Patel A; Marola OJ; Shrager P; Zack DJ; Libby RT; Welsbie DS
Exp Eye Res; 2018 Jun; 171():54-61. PubMed ID: 29526794
[TBL] [Abstract][Full Text] [Related]
47. Calpain-mediated cleavage of collapsin response mediator protein(CRMP)-2 during neurite degeneration in mice.
Touma E; Kato S; Fukui K; Koike T
Eur J Neurosci; 2007 Dec; 26(12):3368-81. PubMed ID: 18052987
[TBL] [Abstract][Full Text] [Related]
48. Chemical genetic-mediated spatial regulation of protein expression in neurons reveals an axonal function for wld(s).
Cohen MS; Ghosh AK; Kim HJ; Jeon NL; Jaffrey SR
Chem Biol; 2012 Feb; 19(2):179-87. PubMed ID: 22365601
[TBL] [Abstract][Full Text] [Related]
49. SARM1 Ablation Is Protective and Preserves Spatial Vision in an In Vivo Mouse Model of Retinal Ganglion Cell Degeneration.
Finnegan LK; Chadderton N; Kenna PF; Palfi A; Carty M; Bowie AG; Millington-Ward S; Farrar GJ
Int J Mol Sci; 2022 Jan; 23(3):. PubMed ID: 35163535
[TBL] [Abstract][Full Text] [Related]
50. The slow Wallerian degeneration gene in vivo protects motor axons but not their cell bodies after avulsion and neonatal axotomy.
Adalbert R; Nógrádi A; Szabó A; Coleman MP
Eur J Neurosci; 2006 Oct; 24(8):2163-8. PubMed ID: 17074042
[TBL] [Abstract][Full Text] [Related]
51. Wallerian degeneration: an emerging axon death pathway linking injury and disease.
Conforti L; Gilley J; Coleman MP
Nat Rev Neurosci; 2014 Jun; 15(6):394-409. PubMed ID: 24840802
[TBL] [Abstract][Full Text] [Related]
52. Differential protection of neuromuscular sensory and motor axons and their endings in Wld(S) mutant mice.
Oyebode OR; Hartley R; Singhota J; Thomson D; Ribchester RR
Neuroscience; 2012 Jan; 200():142-58. PubMed ID: 22062136
[TBL] [Abstract][Full Text] [Related]
53. Wld(S), Nmnats and axon degeneration--progress in the past two decades.
Feng Y; Yan T; He Z; Zhai Q
Protein Cell; 2010 Mar; 1(3):237-45. PubMed ID: 21203970
[TBL] [Abstract][Full Text] [Related]
54. MEK inhibitor U0126 reverses protection of axons from Wallerian degeneration independently of MEK-ERK signaling.
Evans C; Cook SJ; Coleman MP; Gilley J
PLoS One; 2013; 8(10):e76505. PubMed ID: 24124570
[TBL] [Abstract][Full Text] [Related]
55. Signaling mechanisms regulating Wallerian degeneration.
Freeman MR
Curr Opin Neurobiol; 2014 Aug; 27():224-31. PubMed ID: 24907513
[TBL] [Abstract][Full Text] [Related]
56. Gene therapy targeting SARM1 blocks pathological axon degeneration in mice.
Geisler S; Huang SX; Strickland A; Doan RA; Summers DW; Mao X; Park J; DiAntonio A; Milbrandt J
J Exp Med; 2019 Feb; 216(2):294-303. PubMed ID: 30642945
[TBL] [Abstract][Full Text] [Related]
57. Novel role of SARM1 mediated axonal degeneration in the pathogenesis of rabies.
Sundaramoorthy V; Green D; Locke K; O'Brien CM; Dearnley M; Bingham J
PLoS Pathog; 2020 Feb; 16(2):e1008343. PubMed ID: 32069324
[TBL] [Abstract][Full Text] [Related]
58. Rescue of peripheral and CNS axon defects in mice lacking NMNAT2.
Gilley J; Adalbert R; Yu G; Coleman MP
J Neurosci; 2013 Aug; 33(33):13410-24. PubMed ID: 23946398
[TBL] [Abstract][Full Text] [Related]
59. Wld S protein requires Nmnat activity and a short N-terminal sequence to protect axons in mice.
Conforti L; Wilbrey A; Morreale G; Janeckova L; Beirowski B; Adalbert R; Mazzola F; Di Stefano M; Hartley R; Babetto E; Smith T; Gilley J; Billington RA; Genazzani AA; Ribchester RR; Magni G; Coleman M
J Cell Biol; 2009 Feb; 184(4):491-500. PubMed ID: 19237596
[TBL] [Abstract][Full Text] [Related]
60. Wallerian degeneration, wld(s), and nmnat.
Coleman MP; Freeman MR
Annu Rev Neurosci; 2010; 33():245-67. PubMed ID: 20345246
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
